At an FDA advisory panel hearing held in September to evaluation liraglutide's feasible obesity indication, David W Cooke, MD, affiliate professor of pediatrics and scientific director of pediatric endocrinology at Johns Hopkins University, Baltimore, Maryland, said, "I thought the data inc